肺纤维化急性加重患者短期内死亡危险因素分析

来源期刊：广州医药 | 1-4 发布时间：2021-11-28 收稿时间：2025/11/13 17:40:10 阅读量：14

作者：: 赵稳,

王延生,

周霞,

王小凡,

吴德阳,

熊淑琪,

徐军,

刘明,

关键词：: 特发性肺纤维化结缔组织病相关性纤维化间质性肺疾病急性加重危险因素; Idiopathic pulmonary fibrosis Connective tissue disease associated with fibrotic interstitial lung disease Acute exacerbatioin Risk factor

DOI：: 10.3969/j.issn.1000-8535.2020.05.001

收稿时间：: 2020-05-20
修订日期：
接收日期：
引用总数：: 0

目的探讨特发性肺纤维化(IPF)患者和结缔组织病相关性纤维化间质性肺疾病(CTD-fILD)患者急性加重(AE)的短期内死亡的危险因素。方法回顾性分析2017年10月—2019年9月在深圳大学和广州医科大学附属第一医院住院的25例 AE-CTD-fILD和26例AE-IPF患者临床信息,Kaplan-Merier法对两组患者进行生存分析,Cox回顾分析年龄、性别、吸烟、白细胞总数、C反应蛋白、红细胞沉降率及肿瘤指标在急性加重患者死亡中的作用。结果与AE-CTD-fILD比较,AE-IPF患者组男性比例、年龄、吸烟比例较高,红细胞沉降率较低(24/26 vs 10/25,P<0.001;63.77±9.97 vs 58.00±10.32,P=0.048;16/26 vs 9/25,P=0.02;28.07±29.45 vs 64.35±40.34,P=0.002 );90天内,26例AE-IPF患者11例死亡,25例AE-CTD-fILD患者5例死亡,死亡率无明显差异(42.3% vs 20%,P=0.073);Cox回归分析显示,白细胞计数是AE-IPF和AE-CTD-fILD患者的死亡危险因素(HR=1.305,P=0.001;HR=1.529,P=0.009);CA15-3是AE-IPF患者死亡危险因素(HR=1.015,P=0.005)。结论急性加重IPF和CTD-fILD患者短期内死亡风险相似,白细胞计数及外周CA15-3水平可能是肺纤维化急性加重患者短期内死亡的危险因素。

1、 HIRAI K, HOMMA T, YAMAGUCHI F, et al. Acute exacerbation of idiopathic pulmonary fibrosis induced by pertussis: the first case report[J]. BMC Pulm Med, 2019,19(1):15.

2、 D'ALESSANDRO-GABAZZA C N, KOBAYASHI T, YASUMA T, et al. A Staphylococcus pro-apoptotic peptide induces acute exacerbation of pulmonary fibrosis[J]. Nature commun, 2020,11(1):1539.

3、 SUZUKI A, KIMURA T, KATAOKA K, et al. Acute exacerbation of idiopathic pulmonary fibrosis triggered by Aspergillus empyema[J]. Respir Med Case Rep, 2018(23):103-106.

4、 WOOTTON S C, KIM D S, KONDOH Y, et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2011,183(12):1698-702.

5、 TOMIOKA H, SAKURAI T, HASHIMOTO K, et al. Acute exacerbation of idiopathic pulmonary fibrosis:role of Chlamydophila pneumoniae infection[J]. Respirol, 2007,12(5):700-706.

6、 WENG D, CHEN X Q, QIU H, et al. The role of infection in acute exacerbation of idiopathic pulmonary fibrosis[J]. Mediators Inflamm, 2019(2019):1-10.

7、 USUI Y, KAGA A, SAKAI F, et al. A cohort study of mortality predictors in patients with acute exacerbation of chronic fibrosing interstitial pneumonia[J]. BMJ, 2013,3(7):e002971.

8、 ENOMOTO N, OYAMA Y, ENOMOTO Y, et al. Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis[J]. Chron Respir Dis, 2019(16):1-8.

9、 SUZUKI A, KONDOH Y, BROWN K K, et al. Acute exacerbations of fibrotic interstitial lung diseases[J]. Respirology, 2020, 25(5):525-534.

10、 WELLS A U, DENTON C P. Interstitial lung disease in connective tissue disease-mechanisms and management[J]. Nature Rev Rheumatol, 2014,10(12):728-739.

11、 CHURG A, MüLLER N L, SILVA C I, et al. Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias[J]. Am J Surg Pathol, 2007,31(2):277-284.

12、 RYERSON C J, CORTE T J, LEE J S, et al. A standar-dized diagnostic ontology for fibrotic interstitial lung disease. An International Working Group Perspective[J]. Am J Respir Crit Care Med, 2017,196(10):1249-1254.

13、 AL-HAMEED F M, SHARMA S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis[J]. Can Respir J, 2004,11(2):117-122.

14、 COLLARD H R, RYERSON C J, CORTE T J, et al. Acute exacerbation of idiopathic pulmonary fibrosis:An international working group report[J]. Am J Respir Crit Care Med,2016,194(3):265-275.

15、 CAO M, SHENG J, QIU X, et al. Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study[J]. BMC Pulm Med, 2019,19(1):215.

16、 TACHIKAWA R, TOMII K, UEDA H, et al. Clinical features and outcome of acute exacerbation of interstitial pneumonia: collagen vascular diseases-related versus idiopathic[J]. Respiration, 2012,83(1):20-27.

17、 SONG J W, HONG S B, LIM C M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome[J]. Eur Respir J,2011,37(2):356-363.

18、 MATHAI S C, DANOFF S K. Management of interstitial lung disease associated with connective tissue disease[J]. BMJ, 2016(352):h6819.

19、 RAGHU G, COLLARD H R, EGAN J J, et al. An official ATS/ERS/JRS/ALAT statement: idiopathicpulmonary fibrosis: evidence-based guidelines for diagnosis and management[J]. Am J Respir Crit Care Med,2011,83(6):788-824.